TNF and psoriasis: Finally, a large meta-analysis including 38 randomized controlled trials showed no significant difference in risk of major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, or cardiovascular death) in patients with psoriasis (n = 18,024) treated with biologic therapies including anti-IL-12/23, TNF-α inhibitors, and anti-IL-17A agents (118).